Kyongbo Pharmaceutical Co., Ltd

KOSE:A214390 Stock Report

Market Cap: ₩129.1b

Kyongbo Pharmaceutical Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Kyongbo Pharmaceutical.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth22.0%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Analysis Article • Sep 24

Kyongbo Pharmaceutical Co., Ltd's (KRX:214390) Shares Climb 27% But Its Business Is Yet to Catch Up

Kyongbo Pharmaceutical Co., Ltd ( KRX:214390 ) shareholders have had their patience rewarded with a 27% share price...
Analysis Article • Sep 11

Does Kyongbo Pharmaceutical (KRX:214390) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Jun 19

Kyongbo Pharmaceutical Co., Ltd's (KRX:214390) Business Is Trailing The Market But Its Shares Aren't

When close to half the companies in Korea have price-to-earnings ratios (or "P/E's") below 12x, you may consider...
Analysis Article • Feb 19

Kyongbo Pharmaceutical Co., Ltd (KRX:214390) Investors Are Less Pessimistic Than Expected

Kyongbo Pharmaceutical Co., Ltd's ( KRX:214390 ) price-to-earnings (or "P/E") ratio of 33.2x might make it look like a...
Analysis Article • Mar 09

Kyongbo Pharmaceutical (KRX:214390) Has A Somewhat Strained Balance Sheet

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Feb 02

What Type Of Shareholders Own The Most Number of Kyongbo Pharmaceutical Co., Ltd (KRX:214390) Shares?

The big shareholder groups in Kyongbo Pharmaceutical Co., Ltd ( KRX:214390 ) have power over the company. Large...
Analysis Article • Jan 12

Kyongbo Pharmaceutical Co., Ltd's (KRX:214390) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Kyongbo Pharmaceutical's (KRX:214390) stock is up by a considerable 42% over the past three months. However, we decided...
Analysis Article • Dec 25

Did You Miss Kyongbo Pharmaceutical's (KRX:214390) Impressive 107% Share Price Gain?

Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right business to buy shares...
Analysis Article • Dec 08

Is Kyongbo Pharmaceutical (KRX:214390) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Nov 18

Does Kyongbo Pharmaceutical's (KRX:214390) Statutory Profit Adequately Reflect Its Underlying Profit?

Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kyongbo Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSE:A214390 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2026269,642347-40,11411,233N/A
12/31/2025264,104182-34,1397,456N/A
9/30/2025252,2012,356-29,7886,906N/A
6/30/2025243,445406-22,0371,055N/A
3/31/2025236,5442,295-17,701-1,425N/A
12/31/2024238,5564,639-13,026149N/A
9/30/2024240,5104,925-7,8404,940N/A
6/30/2024236,8614,608-17,502-5,120N/A
3/31/2024231,0045,364-9,995-252N/A
12/31/2023216,3572,974-5,7984,844N/A
9/30/2023212,9022,361-17,323-5,983N/A
6/30/2023207,6511,641-5,5045,936N/A
3/31/2023201,204-289-2,49810,059N/A
12/31/2022196,265611-3,05710,127N/A
9/30/2022180,396-3,8994,03017,902N/A
6/30/2022170,024-8,48713,28928,205N/A
3/31/2022169,982-8,8543,29419,600N/A
12/31/2021170,660-7,495-35617,968N/A
9/30/2021177,259-4,072-1,26218,473N/A
6/30/2021193,0372,9376,14922,876N/A
3/31/2021207,1728,9172,64018,187N/A
12/31/2020215,2859,4048,35920,795N/A
9/30/2020215,3487,2501,56922,080N/A
6/30/2020205,9076,232-11,52911,206N/A
3/31/2020198,5975,134-1,30022,090N/A
12/31/2019191,7065,285N/A23,668N/A
9/30/2019196,17110,079N/A12,702N/A
6/30/2019201,16610,920N/A10,642N/A
3/31/2019198,99811,231N/A-1,743N/A
12/31/2018201,34413,116N/A-1,138N/A
9/30/2018196,80514,443N/A7,851N/A
6/30/2018193,14717,740N/A21,426N/A
3/31/2018193,55518,494N/A27,019N/A
12/31/2017191,66117,963N/A25,805N/A
9/30/2017186,98017,082N/A25,296N/A
6/30/2017187,22312,704N/A19,463N/A
3/31/2017187,21611,817N/A16,757N/A
12/31/2016186,72612,706N/A25,329N/A
9/30/2016188,60419,611N/A13,830N/A
6/30/2016187,02523,496N/A4,095N/A
3/31/2016179,56125,518N/A7,699N/A
12/31/2015178,03326,110N/A4,240N/A
9/30/2015177,8354,233N/A5,471N/A
6/30/2015173,6683,315N/A7,566N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A214390's forecast earnings growth is above the savings rate (3.1%).

Earnings vs Market: Insufficient data to determine if A214390's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A214390's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A214390's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A214390's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A214390's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/06 01:01
End of Day Share Price 2026/06/05 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kyongbo Pharmaceutical Co., Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Seung-Ho LeeNH Investment & Securities Co., Ltd.